Search results
Showing 541 to 555 of 565 results for oral care
Agenda and papers of the NICE public board meeting on 13 December 2023
Agenda and papers of the NICE public board meeting on 22 March 2023
Agenda and papers of the NICE public board meeting on 20 March 2024
Agenda and papers of the NICE public board meeting on 17 May 2023
Agenda and papers of the NICE public board meeting on 17 July 2024
Agenda and papers of the NICE public board meeting on 16 December 2022
Agenda and papers of the NICE public board meeting on 15 May 2024
Agenda and papers of the NICE public board meeting on 22 July
Evidence-based recommendations on osimertinib (Tagrisso) with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.
Methods for the development of NICE public health guidance (third edition) (PMG4)
This manual describes the methods used by the Centre for Public Health Excellence (CPHE) in NICE to develop and update public health guidance
Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults.
Evidence-based recommendations on ribociclib (Kisqali) with an aromatase inhibitor for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.
Show all sections
Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)
Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.
View recommendations for TA380Show all sections
More than 20,000 people benefitting from innovative migraine pills recommended by NICE
A new type of tablet specifically designed to prevent migraine is transforming lives across England, with the number of people being prescribed these medicines more than tripling in just one year.
First HIV prevention injection for people unable to have daily PrEP recommended
A ground-breaking HIV-1 prevention injection has been recommended by NICE, marking a significant advance for a small group of adults and young people unable to have daily pre-exposure prophylaxis (PrEP) tablets.